Correction: Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Applying Clinical Trial Evidence for Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema to Clinical Practice

  • By

  • Sobha Sivaprasad

  • Michael W. Stewart

  • Charles C. Wykoff

  • David Eichenbaum

  • Jean-Francois Korobelnik

  • Paolo Lanzetta

  • Varun Chaudhary

  • Chui Ming Gemmy Cheung

  • Richard Gale

  • Marion R. Munk

  • Taiji Sakamoto

  • Andreas Stahl

  • Javier Zarranz-Ventura

  • Tien Yin Wong

  • Frank G. Holz

  • Anat Loewenstein

  • October 20, 2026

Share

  • 1

    A correction to the article on applying clinical trial evidence for aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema was published online on August 7, 2026.

  • 2

    The correction was published in Eye.

  • 3

    The correction states that typos in the article text were corrected.

  • 4

    The correction states that typos in the references, funding statement, and competing interest section were corrected.

  • 5

    The original article has undergone correction.

Original Source(s)

Correction: Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice

  • by Sobha Sivaprasad, Michael W. Stewart, Charles C. Wykoff, David Eichenbaum, Jean-Francois Korobelnik, Paolo Lanzetta, Varun Chaudhary, Chui Ming Gemmy Cheung, Richard Gale, Marion R. Munk, Taiji Sakamoto, Andreas Stahl, Javier Zarranz-Ventura, Tien Yin Wong, Frank G. Holz, Anat Loewenstein

  • October 20, 2026

Related Content

Smoking Cessation Duration and Diabetic Microvascular Complications

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

Data and Temporal Risk Concerns of Semaglutide and NAION